Recent Updates — TCRT
The Nasdaq Stock Market notified Alaunos Therapeutics of non-compliance with the $2,500,000 minimum stockholders' equity listing standard in April 2026 and issued a delisting notice on October 5, 2026. Following a private placement financing completed on October 14, 2026, Nasdaq confirmed on October 22 that the company has regained compliance with the Stockholders’ Equity Requirement. Consequently, Nasdaq closed the matter and cancelled the scheduled hearing before the Nasdaq Hearings Panel for November 10, 2026, allowing the common stock to remain listed on The Nasdaq Capital Market. Alaunos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.
Alaunos Therapeutics completed its merger with Velaris Therapeutics and closed a private placement raising approximately $350 million in gross proceeds. The transaction involved issuing 687,789 shares of common stock at $1.4357 per share and 243,063 shares of Series C Preferred Stock at $1,435.70 per share. An affiliate of Fairmount Healthcare Fund II waived a cash settlement right on approximately $9 million of preferred shares to support equity classification. The financing enabled the company to regain compliance with Nasdaq’s $2.5 million stockholders’ equity requirement, potentially avoiding delisting pending regulatory confirmation. Alaunos Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare diseases.
Alaunos Therapeutics completed its acquisition of Velaris Therapeutics, exchanging shares for all outstanding equity interests. Concurrently, the company closed a private placement raising approximately $350 million from institutional investors led by Fairmount. The financing will fund Velaris's pipeline development and operations through 2029. Alaunos operates in the biotechnology sector.
The Nasdaq Stock Market notified Alaunos Therapeutics that its common stock is subject to delisting for failing to maintain the required minimum stockholders' equity of $2,500,000 under Listing Rule 5550(b)(1). The company plans to request a hearing before the Nasdaq Hearings Panel to stay any further suspension or delisting action. Alaunos is exploring strategic alternatives and working with a financial advisor to complete transactions intended to regain compliance. There is no assurance that the panel will grant continued listing or that any transaction will be consummated. The company operates in the biotechnology sector, focusing on drug discovery.
Alaunos Therapeutics, Inc. completed a registered direct offering of common stock on September 21, 2026, raising approximately $915,400 in net proceeds after deducting placement agent fees and expenses. The company issued 380,469 shares at $1.46 per share and 386,654 pre-funded warrants exercisable at $0.001 per share to accredited investors, with gross proceeds totaling approximately $1,120,000. Dawson James Securities, Inc. served as the exclusive placement agent, receiving an 8% cash fee. Proceeds are designated for general corporate purposes and working capital. Officers and directors entered into 15-day lock-up agreements restricting transfers of their holdings. Alaunos Therapeutics is a biotechnology company focused on developing novel therapeutics for obesity and metabolic disorders.